Sep 8, 2026 8:17am EDT Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
Sep 2, 2026 8:30am EDT Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference